Sanofi Hampered By Fitusiran Clinical Hold In Hemophilia
Reports Of Non-Fatal Thrombotic Events
The French major stressed to Scrip that patients enrolled in its fitusiran clinical trials often have other health issues and various co-morbidities, so it is too early to know if the adverse events are treatment-related.
You may also be interested in...
Sanofi executives are upbeat about the potential advantages of its monoclonal antibody-based approach to the prevention of RSV infections in infants, the future growth of the company’s Dupixent franchise, and the progress of its novel anticancers.
Dupixent was Sanofi’s top-selling product in 2020, but its vaccines division also saw significant growth in the year led by its differentiated influenza vaccines, which helped drive the big pharma’s business during the year, accompanied by significant cost savings.
The French drugmaker's follow up to Myozyme – avalglucosidase alfa – is in line for a potential US approval by May next year after the US FDA agreed to a speedy review of the enzyme replacement therapy, unlike its European counterparts.